Recursion Pharmaceuticals, Inc. (RXRX) financial statements and ratios from SEC XBRL: revenue $74.68M (TTM), net margin -863.4%, revenue growth -56.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $74.68M |
| Net Margin | -863.4% |
| Revenue Growth (YoY) | -56.1% |
| EPS Growth (YoY) | -56.0% |
| FCF Growth (YoY) | -39.2% |
| Price / Book | 1.73 |
| Price / Sales | 26.65 |
| FCF Yield | -18.4% |
| Altman Z-Score | 0.25 (distress) |
| Sector P/E (Healthcare) | 21.6 |
RXRX overview · RXRX earnings · RXRX KPIs · RXRX investor relations · RXRX ownership · RXRX peers · RXRX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.